Dilsher S. Dhoot

University of Southern California — United States

Medicine · Health Sciences

20h-index2.1kcitations58works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Retinal Diseases and Treatments(39), Retinal Imaging and Analysis(26), Retinal and Optic Conditions(24), Retinal and Macular Surgery(11), Glaucoma and retinal disorders(9)

Publications57 total

Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy
Journal of VitreoRetinal Diseases·2025· 1 cited
Impact of Central Subfield Thickness Fluctuations on Visual Outcomes in Neovascular Age-Related Macular Degeneration in the VIEW Trials
Journal of VitreoRetinal Diseases·2025Open Access
Treatment of Retinal/Choroidal Vascular Diseases by Sustained Delivery of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors
American Journal of Ophthalmology·2025· 3 cited
Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE
American Journal of Ophthalmology·2025· 6 citedOpen Access
Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema
Ophthalmology Retina·2025· 5 citedOpen Access
Longitudinal Changes in Diabetic Retinopathy Severity: Learnings from PANORAMA
Ophthalmology Retina·2024· 1 citedOpen Access
Ocular and Systemic Risk Factors for Disease Worsening Among Patients with NPDR
Ophthalmology Retina·2023· 6 cited
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
The Lancet·2023· 375 citedOpen Access
KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema
American Journal of Ophthalmology·2023· 47 citedOpen Access
Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion
Eye·2023· 5 citedOpen Access
INCIDENCE OF NEW DIABETIC MACULAR EDEMA IN FELLOW EYES OF PATIENTS IN THE VISTA AND VIVID STUDIES
Retina·2022· 6 citedOpen Access
Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials
Eye·2022· 2 citedOpen Access
A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy
Ophthalmology Science·2022· 20 citedOpen Access
Rates of Suspected Endophthalmitis Following Intravitreal Injections in Clinical Practices in the United States
Ophthalmic surgery, lasers & imaging retina·2021· 14 cited
Antivascular Endothelial Growth Factor Dosing Frequency and Visual Outcomes in Macular Edema Following Central Retinal Vein Occlusion
Journal of VitreoRetinal Diseases·2021· 3 citedOpen Access
Private Equity's Game Plan and Why it Should Matter to Us
Ophthalmic surgery, lasers & imaging retina·2020· 3 cited
Baseline Factors Associated with Diabetic Retinopathy Improvement in RIDE/RISE
Ophthalmology Retina·2020· 1 citedOpen Access
The Retina Illustrated
2019
Sustained Diabetic Retinopathy Severity Improvement with Intravitreal Aflibercept in Diabetic Macular Edema: A Post Hoc Analysis of the VISTA and VIVID Trials
Investigative Ophthalmology & Visual Science·2019Open Access
Visual Acuity Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinal Vein Occlusion in Routine Clinical Practice
2019
page 1 of 3Next →

Frequent Co-authors

Dante J. Pieramici(14), Nathan Steinle(13), Robert L. Avery(12), Alessandro Castellarin(12), Charles C. Wykoff(10), Robert F. See(10), Ma'an Nasir(9), Hadi Moini(7), Stephen Couvillion(6), Alyson J. Berliner(6), Rishi P. Singh(5), Robert Vitti(5), Weiming Du(5), David S. Boyer(4), Caroline R. Baumal(4), Dennis M. Marcus(4), Melvin Rabena(4), Peter K. Kaiser(4), Carlos Quezada-Ruiz(4), Kimberly Reed(4)